Skip to search formSkip to main contentSkip to account menu

BE 16627B

Known as: BE-16627B, BE16627B 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2006
2006
Apoptotic induction by BE16627B on human malignant glioma cell lines by an anti-matrix metalloproteinase agent
We have elucidated the pharmacological action of the anti-matrix metalloproteinase inhibitor BE16627B on glioma cells. The study… 
Review
1997
Review
1997
[CDK and MMP inhibitors].
CDK inhibitor, Butyrolactone I inhibited CDK1, 2 and 5 in CDKs. In syncronized human lung fibroblast WI38 cells, it inhibited G1… 
1994
1994
Inhibition of Growth of Human Tumor Cells in Nude Mice by a Metalloproteinase Inhibitor
The effects of a new metalloproteinase inhibitor, BE16627B [L-N-(N-hydroxy-2-isobutylsuccinynamoyl)-seryl-L-valine, MW: 375.2… 
1993
1993
Inhibition of metalloproteinase activity of rheumatoid arthritis synovial cells by a new inhibitor [BE16627B;l-N-(N-hydroxy-2-isobutylsuccinamoyl)-seryl-l-valine]
The effect of a new metalloproteinase (MP) inhibitor [BE16627B;l-N-(N-hydroxy-2-isobutylsuccinamoyl)-seryl-l-valine, MW: 375.2… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)